Compare Ryanair Holdings plc (RYAAY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Sana Biotechnology Inc — how do they compare? Ryanair Holdings plc trades at $54.25 (market cap $27.24B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: Ryanair Holdings plc is far larger — about 28.7× Sana Biotechnology Inc's market cap, and Ryanair Holdings plc pays a 1.66% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| RYAAY | SANA | |
|---|---|---|
Market Cap | $27.24B | $947.48M |
Sector | Industrials | Health |
52-Week High | $73.82 | $5.92 |
52-Week Low | $53.24 | $2.68 |
Enterprise Value | $24.19B | $860.73M |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RYAAY trades at $54.37, down 1.79% today, with bearish technical signals but strong fundamentals including 12.13% net margins and 22.41% ROE. Recent earnings show mixed results with a Q1 beat but Q2 miss, while Q3 expectations are high at $3.38 EPS. The company maintains robust cash flow from operations at $3.42B despite net cash flow turning negative in 2025. Analyst consensus remains positive with 62.5% buy ratings, though recent news highlights concerns about oil price exposure and reduced traffic forecasts.
The outlook balances strong profitability and market position against near-term headwinds from fuel costs and competitive pricing. Investment opportunity lies in Ryanair's industry-leading efficiency and potential market share gains during industry consolidation. Key risks include unhedged fuel costs, winter capacity cuts, and macroeconomic sensitivity. The stock's current valuation at 13.04 P/E appears reasonable if the company can maintain its earnings trajectory amid industry challenges.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
